Home > Neurology > TOXINS 2019 > Spasticity > ASPIRE: High patient and clinician satisfaction

ASPIRE: High patient and clinician satisfaction

Expert
Dr Gerard Francisco, TIRR Memorial Hermann Hospital, USA
Conference
TOXINS 2019
Trial
ASPIRE

Dr Gerard Francisco (TIRR Memorial Hermann Hospital, USA) focused on real-world onabotulinum toxin A treatment utilisation. He evaluated efficacy across multiple aetiologies of spasticity from the Adult Spasticity International Registry (ASPIRE) study. Dr Francisco examined data - derived from the international, multicentre, prospective, observational registry - from adult patients with spasticity either due to stroke (56%), multiple sclerosis, cerebral palsy, traumatic brain injury, spinal cord injury, or other illnesses, treated with onabotulinum toxin A. In total, 730 participants, of whom 37% were previously treatment-naĂŻve to botulinum toxins, received at least one onabotulinum toxin A treatment. Total dosages per treatment session ranged from 45 to 1,038 units. The most common symptoms prompting treatments were equinovarus foot and clenched fist (in stroke). Most physicians and patients reported being "satisfied" or "extremely satisfied" with treatment that helped manage sp...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on